Pharvaris N.V. Files Routine 6-K Report

TL;DR

Pharvaris N.V. filed a routine 6-K, no major news.

AI Summary

Pharvaris N.V. filed a Form 6-K on September 23, 2024, for the month of September 2024. The company, a foreign private issuer, is based in Leiden, The Netherlands, and operates in the Pharmaceutical Preparations industry. This filing is routine and does not appear to contain specific financial updates or material events.

Why It Matters

This filing is a standard disclosure for foreign private issuers and typically indicates ongoing compliance rather than new material information.

Risk Assessment

Risk Level: low — The filing is a standard, periodic report for a foreign private issuer and does not contain any new material information that would typically impact risk.

Key Players & Entities

• Pharvaris N.V. (company) — Filer of the 6-K report
• 001-40010 (company) — Commission File Number for Pharvaris N.V.
• 2834 (company) — Standard Industrial Classification code for Pharmaceutical Preparations

FAQ

From the Filing

0000950170-24-108619.txt : 20240923 0000950170-24-108619.hdr.sgml : 20240923 20240923065103 ACCESSION NUMBER: 0000950170-24-108619 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240923 FILED AS OF DATE: 20240923 DATE AS OF CHANGE: 20240923 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 241314596 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 6-k_september_23.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2   2333 BK Leiden   The Netherlands (Address of principal executive office)   Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐   Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐   Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. PHARVARIS N.V.   Amendment to License Agreement On September 20, 2024, Pharvaris N.V. (the “Company”) entered into an amendment (the “Amendment”) to the March 31, 2016 license agreement (the “AnalytiCon License”) with AnalytiCon Discovery GmbH (“AnalytiCon”) pursuant to which the Company acquired a worldwide, exclusive royalty-bearing license to use a certain proprietary substance class of bradykinin-B2-receptor antagonists with the potential of oral activity, for the purpose of developing, manufacturing and marketing compounds on a global basis for the treatment of, among others, hereditary angioedema. Certain rights associated with deucrictibant, PHVS416 and PHVS719 are subject to the AnalytiCon License. The Amendment clarifies the scope of products upon which the Company will be required to pay a royalty, namely, any licensed product containing a compound within the scope of the Markush general formula (I) of claim 1 of US Patent No. 10,836,748. Each of deucrictibant, PHVS416 and PHVS719 is a royalty-bearing product. The foregoing description of the Amendment does not purport to be complete and is